Poolbeg Pharma (LON:POLB) Reaches New 1-Year High – Should You Buy?

Poolbeg Pharma PLC (LON:POLB) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as GBX 9 and last traded at GBX 8.70, with a volume of 3810007 shares. The stock had previously closed at GBX 8.65.

Analyst Ratings Changes

Separately, Shore Capital Group reiterated a “house stock” rating on shares of Poolbeg Pharma in a report on Monday, July 13th.

Poolbeg Pharma Trading Up 0.6%

The stock has a market cap of £66.42 million, a PE ratio of -9.26 and a beta of 1.80. The business has a 50 day moving average of GBX 7.10 and a 200-day moving average of GBX 5.47.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.